Skip to main content
Article thumbnail
Location of Repository

Improving the outcome of psoriatic arthritis

By Laura Claire Coates


Psoriatic arthritis (PsA) is recognised to have a significant impact on functional impairment, joint damage and quality of life. The aim of this thesis was\ud to investigate tools for early identification, to develop a clinical target for treatment and to utilise these tools within a clinical trial.\ud \ud The ClASssification of Psoriatic ARthritis (CASPAR) criteria, previously developed in established PsA, were tested in patients with recent onset inflammatory\ud arthritis (PsA and controls) to test their discriminative ability in early arthritis. The phenotype of early PsA was investigated further with clinical and ultrasound (US)\ud assessment. Clinical criteria for minimal disease activity (MDA) were developed using a questionnaire. These were subsequently tested in an observational cohort\ud and interventional trial dataset. Finally, they are being utilised prospectively in an RCT addressing the benefits of tight control in PsA.\ud \ud The CASPAR criteria were found to have good sensitivity and specificity for the diagnosis of recent onset PsA. No individual clinical parameters accurately distinguished PsA from other types of inflammatory arthritis, but there was evidence of more oligoarticular disease and enthesitis in PsA compared with rheumatoid arthritis. US imaging showed a small burden of subclinical arthritis and enthesitis\ud but found good correlation between clinical and imaging assessment of disease activity. Criteria for MDA were developed from expert consensus, covering all aspects of psoriatic disease. They were evaluated against the OMERACT filter and have supporting evidence for their validation in terms of truth, discrimination and feasibility. Early unblinded results from the clinical trial indicated that 53%\ud achieved MDA at 12 months.\ud \ud In summary, the CASPAR criteria can be used for early classification of PsA. In addition, a new composite outcome measure has been developed and validated and is now being utilised in a clinical trial

Publisher: Section of Musculoskeletal Disease (Leeds)
Year: 2010
OAI identifier:

Suggested articles


  1. (1980). [Controlled double blind study on the effectiveness and adverse effects of acemetacin and indomethacin in the treatment of psoriatic arthritis]."
  2. (1997). [Prevalence of post-traumatic psoriatic rheumatism]."
  3. (1995). 20 MHz sonography, colorimetry and image analysis in the evaluation of psoriasis vulgaris."
  4. (1976). 99mTc in evaluation of sacro-iliac arthritis."
  5. (2004). A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis."
  6. (2003). A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis--'DIP or not DIP revisited'." Rheumatology (Oxford)
  7. (2007). A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis."
  8. (1976). A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease."
  9. (2011). A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis."
  10. (2008). A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis."
  11. (2001). A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis."
  12. (1997). A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production."
  13. (2007). A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis."
  14. (2004). A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis."
  15. (1985). A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis."
  16. (2008). A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci."
  17. (2006). A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same?"
  18. (2001). A method to score radiographic change in psoriatic arthritis."
  19. (2010). A modified Sharp score demonstrates disease progression in established psoriatic arthritis." Arthritis Care Res (Hoboken)
  20. (1995). A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis."
  21. (1994). A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index."
  22. (1994). A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index."
  23. (2003). A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience."
  24. (2005). A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis."
  25. (2007). A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis."
  26. (1991). A re-evaluation of the osteoarticular manifestations of psoriasis."
  27. (2009). A strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study."
  28. (2006). A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment."
  29. (2008). A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index."
  30. (2009). Abatacept in psoriatic arthritis: results of a phase II study."
  31. (1989). Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser--Doppler flowmetry and immunocytochemical techniques."
  32. (2009). Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)."
  33. (2007). Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial."
  34. (2005). Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial."
  35. (1995). American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis."
  36. (1999). An in vivo study of the microlymphatics in psoriasis using fluorescence microlymphography."
  37. (2008). An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral antiinflammatory agent, apremilast."
  38. (1971). Ankylosing spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter's disease. A comparative study."
  39. (2001). Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.[see comment]."
  40. (2009). Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis."
  41. (2007). Anti-cyclic citrullinated peptide antibody determination in synovial fluid of psoriatic arthritis."
  42. (2005). Anti-TNF therapy: where have we got to in 2005?"
  43. (2006). Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation."
  44. (2005). Antibodies to cyclic citrullinated peptides in psoriatic arthritis."
  45. (2009). Application of a new composite measure of minimal disease activity in patients with psoriatic arthritis treated with adalimumab: subanalysis of the ADEPT trial."
  46. (2010). Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis."
  47. (2009). ASDAS, a highly discriminatory ASASendorsed disease activity score in patients with ankylosing spondylitis."
  48. (1993). Assessment of area of involvement in skin disease: a study using schematic figure outlines."
  49. (2003). Assessment of enthesitis in ankylosing spondylitis."
  50. (2003). Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study."
  51. (1996). Association between ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis: reality or fiction?"
  52. (1992). B-scanning evaluation with image analysis of psoriatic skin."
  53. (1999). Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis.
  54. (2007). Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis."
  55. (1980). Bone scintigraphy in psoriasis (author's transl)]."
  56. (2000). Case definition of psoriatic arthritis." Lancet 356(9247): 2095; author reply
  57. (1964). Cervical Spine in Psoriasis and in Psoriatic Arthritis."
  58. (1998). Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy."
  59. (2006). Classification criteria for psoriatic arthritis: development of new criteria from a large international study."
  60. (1994). Classification of clinical subsets in psoriatic arthritis.[see comment]."
  61. (1999). Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease."
  62. (2005). Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial."
  63. (2003). Clinical and radiological changes during psoriatic arthritis disease progression."
  64. (2010). Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria."
  65. (2004). Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis." Rheumatology (Oxford)
  66. (1995). Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model."
  67. (1983). Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'."
  68. (1988). Clinical observations on nail changes in psoriasis."
  69. (1999). Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis."
  70. (2002). Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study."
  71. (2008). Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses."
  72. (1995). Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study."
  73. (2001). Comparison of Disability and Quality of Life in Rheumatoid and Psoriatic Arthritis."
  74. (2008). Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial."
  75. (2004). Comparison of red and green laser doppler imaging of blood flow."
  76. (1996). Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study."
  77. (2010). Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial."
  78. (2007). Consensus on a core set of domains for psoriatic arthritis."
  79. (2006). Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept."
  80. (1999). Control of cutaneous blood vessels in psoriatic plaques."
  81. (2006). Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis."
  82. (1998). Corticosteroid prescribing in rheumatoid arthritis and psoriatic arthritis."
  83. (2004). Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?"
  84. (1996). Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging."
  85. (2005). Dactylitis in psoriatic arthritis: a marker for disease severity?"
  86. (2003). Dactylitis involving most of the fingers."
  87. (2006). Defining remission in psoriatic arthritis."
  88. (1994). Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index."
  89. (2003). Deriving an operational definition of low disease activity state in rheumatoid arthritis."
  90. (2006). Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard"."
  91. (2009). Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)."
  92. (2004). Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis."
  93. (2008). Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis."
  94. (2009). Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index."
  95. (2010). Development of a Composite Disease Activity Index (CPDAI) in Psoriatic Arthritis." Annals of the Rheumatic Diseases accepted.
  96. (2010). Development of a Disease Severity and Responder Index for psoriatic arthritis – report of the psoriatic arthritis special interest group at OMERACT10 "
  97. (2009). Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis."
  98. (2005). Development of an assessment tool for dactylitis in patients with psoriatic arthritis."
  99. (2007). Diagnostic reliabilty of low-field magnetic resonance imaging (MRI) for the study of nail and distal interphalangeal (DIP) joint in psoriatic arthritis (PsA)."
  100. (1994). Diagnostic ultrasound in dermatology: current uses and future potential."
  101. (1999). Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis."
  102. (1995). Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthritis demonstrated by contrast-enhanced (Gd-DTPA) magnetic resonance imaging."
  103. (1998). Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?"
  104. (2005). Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis."
  105. (2005). Dynamic magnetic resonance of the wrist in psoriatic arthritis reveals imaging patterns similar to those of rheumatoid arthritis."
  106. (2001). Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques."
  107. (2008). Early psoriatic arthritis: the clinical spectrum."
  108. (2005). Early psoriatic arthritis."
  109. (2004). Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial."
  110. (1989). Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis."
  111. (2005). Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebocontrolled trial (ASSERT)."
  112. (2004). Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, - 198 -randomized, placebo-controlled clinical trial."
  113. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)."
  114. (2003). Efficacy of acitretin and commercial tanning bed therapy for psoriasis."
  115. (2001). Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.[see comment]."
  116. (2003). Efficacy of infliximab in resistant psoriatic arthritis."
  117. (2007). Efficacy of leflunomide in psoriatic joint and skin disease: results from a large German prospective observational study of psoriatic arthritis treated with leflunomide (OSPAL)."
  118. (2003). Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis."
  119. (1971). Enthesopathy of rheumatoid and ankylosing spondylitis."
  120. (2008). Environmental risk factors for the development of psoriatic arthritis: results from a case-control study."
  121. (1987). Erosive and subluxing cervical spine disease in patients with psoriatic arthritis."
  122. (2009). Established psoriatic arthritis: clinical aspects."
  123. (2010). Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK."
  124. (2000). Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]."
  125. (2004). Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression."
  126. (2004). Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment."
  127. (2009). Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project."
  128. (2009). Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire."
  129. (2010). Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis."
  130. (2010). Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population."
  131. (2008). Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study."
  132. (2004). Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked." Rheumatology (Oxford)
  133. (2006). Extrasynovial ultrasound abnormalities in the psoriatic finger. Prospective comparative power-doppler study versus rheumatoid arthritis."
  134. (2002). Fast spin echo-T2-weighted sequences with fat saturation in dactylitis of spondylarthritis. No evidence of entheseal involvement of the flexor digitorum tendons."
  135. (2007). Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis." Rheumatology (Oxford)
  136. (2008). Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs." Rheumatology (Oxford)
  137. (2010). Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort." Arthritis Care Res (Hoboken)
  138. (2009). Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis."
  139. (2009). Golimumab administered subcutaneously every four weeks in psoriatic arthritis patients: 52-week health-related quality of life, physical function and health economic results of the randomized placebo-controlled GO-REVEAL study."
  140. (2009). Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study."
  141. (2009). Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study."
  142. (2009). Golimumab, a new, human, TNF alpha antibody, administered every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GOREVEAL study."
  143. (2007). GRAPPA--Group for Research and Assessment of Psoriasis and Psoriatic Arthritis,
  144. (2005). Hepatitis C virus infection in psoriatic arthritis."
  145. (1999). Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis."
  146. (2004). High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease."
  147. (2007). High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone."
  148. (2003). High-resolution multiphoton tomography of human skin with subcellular spatial resolution and picosecond time resolution."
  149. (1997). Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid."
  150. (2002). Histological assessment of the early enthesitis lesion in spondyloarthropathy."
  151. (1985). Histopathology of the nail."
  152. (1986). HLA antigens in psoriatic arthritis."
  153. (2003). HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs."
  154. (1999). HLA-C locus alleles in patients with psoriatic arthritis (PsA)."
  155. (2007). HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis."
  156. (1996). How big is a hand?"
  157. (1989). Human skin histology using high-resolution echography."
  158. (2000). Imaging of sacroiliitis."
  159. (1993). Imaging of the skin with 20-MHz US."
  160. (2001). Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis."
  161. (2009). Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study."
  162. (2008). Incidence and prevalence of psoriatic arthritis: a systematic review."
  163. (1988). Inflammatory joint disease: a comparison of liposome scanning, bone scanning, and radiography."
  164. (2002). Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire."
  165. (2005). Infliximab improves signs and symptoms of psoriatic arthritis:
  166. (2007). Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2."
  167. (2009). Infliximab plus methotrexate significantly improves synovitis and psoriatic lesions in methotrexate naive psoriatic arthritis (PsA) patients: Results of the RESPOND trial."
  168. (2009). International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis."
  169. (2007). International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures."
  170. (2003). Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis."
  171. (2007). Interobserver reliability of the Nail Psoriasis Severity Index."
  172. (1992). Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis."
  173. (2000). Interventions for psoriatic arthritis." Cochrane Database Syst Rev(3):
  174. (2004). Is the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis?"
  175. (2000). Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model."
  176. (1990). Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score."
  177. (2004). Laser Doppler imaging: a developing technique for application in the rheumatic diseases." Rheumatology (Oxford)
  178. (2002). Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis."
  179. (2004). Leflunomide in psoriasis and psoriatic arthritis: a preliminary study."
  180. (2006). Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis."
  181. (1995). Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome."
  182. (2000). Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?"
  183. (2006). Magnetic resonance imaging in psoriatic arthritis: a review of the literature."
  184. (2009). Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis."
  185. (1992). Magnetic resonance imaging in the detection of sacroiliitis."
  186. (2001). Magnetic resonance imaging of the wrist and finger joints in patients with inflammatory joint diseases."
  187. (2003). MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis."
  188. (1991). Measurement of involved surface area in patients with psoriasis."
  189. (2008). Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis."
  190. (2007). Measuring dactylitis in clinical trials: which is the best instrument to use?"
  191. (1971). Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities."
  192. (1964). Methotrexate Therapy in Psoriatic Arthritis; Double-Blind Study on 21 Patients."
  193. (1980). Microcirculation in psoriasis: blood vessels, lymphatics and tissue fluid."
  194. (2005). Minimal disease activity for rheumatoid arthritis: a preliminary definition."
  195. (2010). Modification of minimal disease activity score by replacement of PASI with PGA for patients with psoriatic arthritis treated with adalimumab."
  196. (1995). Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis."
  197. (2008). MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices."
  198. (1995). MRI of the hand in psoriatic and rheumatical arthritis."
  199. (2002). MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions."
  200. (1997). Multiphoton excitation fluorescence microscopy and spectroscopy of in vivo human skin."
  201. (2006). Nail and distal interphalangeal joint in psoriatic arthritis."
  202. (2003). Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.[see comment]."
  203. (1992). Nail psoriasis."
  204. (1994). Natural history of psoriatic arthritis."
  205. (2009). New insights into the pathogenesis and genetics of psoriatic arthritis."
  206. (1999). New method being developed for assessing psoriasis."
  207. (2003). OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint - 203 -pathology definitions, and the OMERACT RA-MRI scoring system."
  208. (2001). Open trial of leflunomide for refractory psoriasis and psoriatic arthritis."
  209. (2003). Optical coherence tomography in contact dermatitis and psoriasis."
  210. (2005). Optimised, low cost, low field dedicated extremity MRI is highly specific and sensitive for synovitis and bone erosions in rheumatoid arthritis wrist and finger joints: comparison with conventional high field MRI and radiography."
  211. (1965). Paravertebral ossification in psoriatic arthritis."
  212. (2007). Patient and physician perception of disease in psoriatic arthritis (PsA). A Multicentre GRAPPA and OMERACT study."
  213. (2006). Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors."
  214. (2007). Photoacoustic imaging of the microvasculature with a high-frequency ultrasound array transducer."
  215. (2007). Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis."
  216. (2007). Predictors for radiological damage in psoriatic arthritis: results from a single centre."
  217. (2001). Predictors of outcome in patients with oligoarthritis: results of a protocol of intraarticular corticosteroids to all clinically active joints."
  218. (2010). Predictors of response to intra-articular steroid injection in psoriatic arthritis."
  219. (1997). Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis."
  220. (2006). Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic druginduced clinical remission: evidence from an imaging study may explain structural progression."
  221. (2005). Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis."
  222. (1999). Progression in psoriatic arthritis: role of time varying clinical indicators."
  223. (1999). Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients."
  224. (2002). Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints."
  225. (1989). Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report." Acta Derm Venereol Suppl (Stockh)
  226. (2005). Psoriasis assessment tools in clinical trials."
  227. (2010). Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA
  228. (2010). Psoriatic arthritis - etanercept, infliximab and adalimumab.
  229. (1991). Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients."
  230. (1987). Psoriatic arthritis (PSA)--an analysis of 220 patients."
  231. (2000). Psoriatic arthritis and human immunodeficiency virus infection in Zambia."
  232. (2005). Psoriatic arthritis and imaging."
  233. (2005). Psoriatic arthritis assessment tools in clinical trials."
  234. (2005). Psoriatic arthritis imaging: a review of scoring methods."
  235. (1999). Psoriatic arthritis: a unified concept twenty years on.[see comment][erratum appears in Arthritis Rheum
  236. (1992). Psoriatic arthritis: clinical response and side effects to methotrexate therapy."
  237. (1987). Psoriatic arthritis: clinical subgroups and histocompatibility antigens."
  238. (2005). Psoriatic arthritis: epidemiology, clinical features, course, and outcome."
  239. (2000). Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution."
  240. (2006). Psoriatic arthritis: one or more diseases?"
  241. (1994). Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease."
  242. (2002). Psoriatic arthritis: performance of rheumatologists in daily practice."
  243. (1979). Psoriatic arthritis.
  244. (1961). Psoriatic arthritis. A comparative radiographic study of rheumatoid arthritis and arthritis associated with psoriasis."
  245. (1994). Psoriatic arthritis. Historical background and epidemiology."
  246. (1973). Psoriatic arthritis."
  247. (1987). Psoriatic arthropathy.
  248. (2003). Psoriatic nails: a prospective clinical study."
  249. (2000). Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging."
  250. (1977). Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films."
  251. (1998). Radiological assessment in psoriatic arthritis."
  252. (1968). Radiological changes in the sacro-iliac joints and spine of patients with psoriatic arthritis and psoriasis."
  253. (1984). Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis."
  254. (2004). Real-time spatial compound ultrasound imaging of skin."
  255. (2008). Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort."
  256. (2004). Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-pannus junction and suprapatellar pouch in inflammatory arthritis: implications for pathogenesis and treatment."
  257. (2007). Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis."
  258. (2004). Relationship of psoriatic arthritis with the other spondyloarthropathies."
  259. (1990). Reliability of measurements of active and damaged joints in psoriatic arthritis."
  260. (2005). Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states."
  261. (2001). Remission in psoriatic arthritis."
  262. (1985). Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis."
  263. (2010). Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors."
  264. (2004). Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased."
  265. (2002). Risk factors for the development of psoriatic arthritis: a population based nested case control study."
  266. (1991). Sacroiliitis: MR imaging findings."
  267. (2007). Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy."
  268. (1998). Sample size calculations in studies of test accuracy."
  269. (2007). Sensitivity and specificity of plain radiographic features of peripheral enthesopathy at major sites in psoriatic arthritis."
  270. (2009). Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis."
  271. (1978). Severe psoriasis--oral therapy with a new retinoid."
  272. (2008). Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years."
  273. (2004). Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease."
  274. (1994). Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy."
  275. (2003). Sonographic study of calcaneal entheses in erosive osteoarthritis, nodal osteoarthritis, rheumatoid arthritis and psoriatic arthritis."
  276. (1999). Sonography of the skin at 100 MHz enables in vivo visualization of stratum corneum and viable epidermis in palmar skin and psoriatic plaques."
  277. (2001). Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society."
  278. (2004). Spondyloarthropathy with entheseal pain. A prospective study in 33 patients."
  279. (1987). Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis."
  280. (2005). Successful treatment of psoriatic onychopachydermo periostitis (POPP) with adalimumab."
  281. (1995). Sulfasalazine in the treatment of spondyloarthropathy."
  282. (1995). Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial."
  283. (1990). Sulphasalazine in psoriatic arthritis: a doubleblind placebo-controlled study."
  284. (1996). Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study."
  285. (1993). Sulphasalazine in the management of psoriatic arthritis."
  286. (2005). Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).[erratum appears in Arthritis Rheum.
  287. (2006). Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis."
  288. (2006). Technical considerations in quantitative blood oxygenation measurement using photoacoustic microscopy in vivo."
  289. (2007). The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients."
  290. (1990). The American College of Rheumatology
  291. (1992). The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study."
  292. (2002). The cervical spine in patients with psoriatic arthritis."
  293. (2004). The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada."
  294. (2007). The comparative effectiveness of antiTNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study."
  295. (2004). The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis."
  296. (2008). The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate."
  297. (1991). The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.[see comment]."
  298. (1951). The exposure treatment of burns."
  299. (1991). The finger-tip unit--a new practical measure."
  300. (1998). The genetics of psoriasis: a complex disorder of the skin and immune system."
  301. (1994). The hyperperfusion of the psoriatic plaque correlates histologically with dilatation of vessels." Acta Derm Venereol Suppl (Stockh)
  302. (2006). The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year."
  303. (2003). The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis."
  304. (2007). The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis."
  305. (1990). The nail in health and disease.
  306. (1998). The OMERACT filter for Outcome Measures in Rheumatology."
  307. (2009). The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands."
  308. (1988). The other arthritides. Roentgenologic features of osteoarthritis, erosive osteoarthritis, ankylosing spondylitis, psoriatic arthritis, Reiter's disease, multicentric reticulohistiocytosis, and progressive systemic sclerosis."
  309. (2007). The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool."
  310. (2008). The performance of CASPAR criteria in early psoriatic arthritis: perliminary results from an italian prospective multicentre study."
  311. (1998). The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A."
  312. (2002). The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy."
  313. (2001). The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide."
  314. (1992). The rule of hand: 4
  315. (1982). The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy."
  316. (1999). The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial."
  317. (1996). The self-administered psoriasis area and severity index is valid and reliable."
  318. (1993). The study of plaques of psoriasis using a scanning laser-Doppler velocimeter."
  319. (2008). The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis."
  320. (1996). The use of high-frequency ultrasound as a method of assessing the severity of a plaque of psoriasis."
  321. (1998). The use of sulfasalazine in psoriatic arthritis: a clinic experience."
  322. (1949). Therapeutic criteria in rheumatoid arthritis."
  323. (2006). Therapeutic effects of a 12-week course of alefacept on nail psoriasis."
  324. (2006). Therapies for dactylitis in psoriatic arthritis. A systematic review."
  325. (2006). Therapies for peripheral joint disease in psoriatic arthritis. A systematic review."
  326. (2006). Therapies for psoriatic nail disease. A systematic review."
  327. (1997). Therapy for psoriatic arthritis: sometimes a conflict for psoriasis."
  328. (2009). Time Trends in Epidemiology and Characteristics of Psoriatic Arthritis Over 3 Decades: A Population-based Study."
  329. (1997). Toe dactylitis in patients with spondyloarthropathy: assessment by magnetic resonance imaging."
  330. (2002). Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial."
  331. (2002). Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.[see comment]."
  332. (1994). Treatment of psoriatic arthritis."
  333. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha."
  334. (2002). Treatment of severe psoriasis and psoriatic arthritis with leflunomide."
  335. (2009). Treatment recommendations for psoriatic arthritis."
  336. (2006). UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register."
  337. (2008). Ultrasonography in the assessment of peripheral joint involvement in psoriatic arthritis : a comparison with radiography, MRI and scintigraphy."
  338. (1999). Ultrasonography in the diagnosis and management of psoriatic dactylitis."
  339. (2006). Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis: a comparison with magnetic resonance imaging, conventional radiography and clinical examination."
  340. (2004). Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination."
  341. (2007). Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis."
  342. (1994). Ultrasound imaging of psoriatic skin: a noninvasive technique to evaluate treatment of psoriasis."
  343. (2009). Ultrasound validation of the Leeds Enthesitis Index in psoriatic arthritis." Annals of the Rheumatic Diseases submitted.
  344. (2008). Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice."
  345. (2009). Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial."
  346. (2010). Validation of minimal disease activity for psoriatic arthritis using interventional trial data."
  347. (2008). Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis."
  348. Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies."

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.